Empowering Life, Driving the Future: Simbay Park Aims to Build a 'Silicon Valley' for the Biopharmaceutical Industry

The biopharmaceutical industry is highly specialized, with complex site selection requirements, substantial capital investment needs, and stringent regulations governing R&D facility certification, environmental impact assessments, and other compliance standards. The burdensome task of establishing operational infrastructure has deterred many scientists, thereby hindering innovation and entrepreneurship within the sector. From the outset of its planning, the Free Trade Zone No. 1 project conducted in-depth industry research to thoroughly understand the bottlenecks facing pharmaceutical R&D and innovation. It precisely positioned the park to provide professional services and industrial support for entrepreneurship and innovation in the pharmaceutical industry. By integrating high-quality industry resources, the project has built an open innovation and incubation service platform featuring a comprehensive ecosystem and specialized functions. This approach significantly reduces upfront investment and optimizes operational costs for pharmaceutical innovators, enabling researchers to conduct R&D activities with greater focus and efficiency.

Shanghai Free Trade Zone No. 1 Life Science and Technology Industrial Park is located at No. 215 Fute South Road, Waigaoqiao Biopharmaceutical Park, in the core area of the Shanghai Free Trade Zone. The park covers a planned area of 500,000 square meters, focusing on the R&D, translation, and manufacturing of innovative drugs, biotechnology and novel therapies, and high-end medical devices. Phase I occupies an area of 51,245.9 square meters, with a total floor area of 142,250.7 square meters. The industrial park is committed to driving innovation by pioneering a comprehensive industrial incubation service system integrating CRO (compliant registration), CDMO (contract research and manufacturing), CSO (contract sales), Capital (investment and financing), CHO (human resources), CMO (brand marketing), and EHS (compliance management). By providing conditions for the translation of R&D achievements and supported by “innovation capital,” the park offers one-stop solutions throughout the entire corporate lifecycle, creating a new model for industrial development and fostering collaboration across the upstream and downstream supply chain, thereby ensuring worry-free development for enterprises in production, education, and research.

Leveraging the unique advantages of its export-oriented regional economy under the “Free Trade Zone + Bonded Zone” model, Free Trade No. 1 builds a bridge for foreign biopharmaceutical companies to enter the Chinese market. It establishes an integrated innovation ecosystem for pharmaceuticals and medical devices, encompassing policy and regulatory affairs, R&D and manufacturing, clinical trials, inspection, testing and certification, investment and financing, market access, and specialized industrial park support. This comprehensive industry service chain incubates domestic and international research teams with advanced R&D achievements.

Leveraging its resource advantages and talent pool, the Park has addressed key bottlenecks in the translation and commercialization of innovations by establishing the Biopharmaceutical Innovative Technology Industry Center. It actively collaborates with leading disciplines at prestigious universities to set up joint university-enterprise laboratories, such as the “Fudan University–Free Trade Zone No. 1 Joint Research Center” and the “Shanghai Jiao Tong University Life and Health Joint Research Center.” Focusing on the sources of innovation, the Park facilitates large-scale scientific collaboration and cross-regional research data exchange, while attracting high-end R&D talent and innovative projects. Meanwhile, recognizing clinical application as a critical link in biopharmaceutical translation, the Park has established a clinical elite training system in partnership with renowned institutions in the Yangtze River Delta, including the Shanghai Institute of Materia Medica (Chinese Academy of Sciences), the Shanghai Institute of Biochemistry and Cell Biology (Chinese Academy of Sciences), Shanghai Jiao Tong University, and Fudan University, thereby cultivating and incubating high-quality talent for industrialization.

Furthermore, as a member unit of the “Yangtze River Delta High-End Medical Equipment Innovation Alliance” and the “Belt and Road Medical Device Innovation and Application Alliance,” Free Trade Zone No. 1 has pioneered China’s first one-stop CRO+CDMO industrial innovation and translation platform aligned with the Marketing Authorization Holder (MAH) system for medical devices. It continues to deepen innovations in the “industry-academia-research-medical application” model, covering the introduction of life health talent projects, innovative incubation, and the industrialization of scientific research achievements, thereby jointly optimizing the domestic R&D environment for biopharmaceutical innovations and helping China’s life science and technology R&D reach an internationally leading level.

Free Trade Zone No. 1 has also established an 8,000-square-meter innovation incubator specifically for start-up biopharmaceutical enterprises—the IDEA LAB. Focused on nurturing and incubating scientific research achievements in the medical industry, the IDEA LAB provides in-depth technical incubation tailored to the healthcare sector, serving as an accelerator for the commercialization of technological innovations by start-ups.

The industrial park has established its own biomedical industry development fund. Over the next five years, it plans to invest RMB 2–4 billion in collaboration with professional investment institutions and medical entrepreneurs to identify future opportunities. Starting with an analysis of the industrial chain structure, Free Trade Zone No. 1 conducts multi-dimensional statistical assessments of companies within the chain—covering scale, profitability, and technology—to create an industry mapping and design diversified investment and financing solutions. These include unsecured customized renovation financing to reduce corporate cash flow risks; diverse financial loan platforms, interest subsidy policies, and financial leasing to help companies lower operational costs and improve efficiency; and access to multiple investment institutions, roadshow platforms, and entrepreneurship competitions to effectively address critical bottlenecks facing enterprises. Furthermore, by assembling a think tank comprising China’s top scientists, entrepreneurs, and investors, and by building project and capital pools, the initiative aims to accelerate the commercialization of scientific achievements, facilitate project implementation, and expand market reach.

Benefiting from the facilitative business environment and industrial resources of Waigaoqiao’s “Free Trade Zone + Bonded Zone,” Free Trade No. 1 has integrated advantageous resources in policy, talent, and industry during its development, with a pronounced agglomeration effect in the pharmaceutical industry chain.

Surrounding Free Trade Zone No. 1 are more than 700 biopharmaceutical companies, generating an economic impact of over RMB 180 billion. The zone accounts for 30% of China’s pharmaceutical market and 25% of its imported medical device market. Leading domestic and international biopharmaceutical giants have established their presence here, fostering a robust biopharmaceutical industry ecosystem.

Growing alongside these multinational pharmaceutical companies is China’s contract research and development services industry. The rising R&D and manufacturing demands of multinational pharma firms in China have generated a substantial volume of outsourcing orders. As a result, the Waigaoqiao Free Trade Zone has developed a comprehensive biopharmaceutical industrial ecosystem, enabling startup pharmaceutical companies within the park to leverage surrounding industrial resources to rapidly advance their R&D projects.

As of December 2020, Free Trade Zone No. 1 has successfully introduced more than 80 innovative biopharmaceutical enterprises. As a cross-border, two-way industrial service platform, Free Trade Zone No. 1 features distinct internationalization and innovation characteristics. While developing high-quality industry infrastructure, the project adheres to the concept of “sharing + platform” to deliver professional, high-quality services. It empowers the entire industry chain—from the global recruitment of life and health talent and project incubation to the commercialization of scientific research achievements—thereby building an internationally leading innovative biotechnology industrial ecosystem community.